瑞普生物(300119) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 was ¥458,238,719.95, a decrease of 14.67% compared to the same period last year[3] - Net profit attributable to shareholders for Q3 2021 was ¥88,606,703.01, down 15.59% year-on-year[3] - The net profit after deducting non-recurring gains and losses was ¥76,522,167.07, a decrease of 22.93% compared to the previous year[3] - The basic earnings per share for Q3 2021 was ¥0.2231, down 15.62% year-on-year[3] - The weighted average return on equity was 3.48%, a decrease of 1.20% compared to the previous year[3] - Operating profit for Q3 2021 was ¥360,731,153.64, up 8.0% from ¥333,863,789.63 in Q3 2020[28] - Net profit attributable to shareholders of the parent company was ¥292,192,032.14, representing a 15.8% increase from ¥252,268,462.31 in the previous year[29] - Basic and diluted earnings per share for Q3 2021 were both ¥0.7358, compared to ¥0.6376 in Q3 2020[29] Assets and Liabilities - Total assets at the end of Q3 2021 reached ¥4,115,630,838.48, an increase of 5.55% from the end of the previous year[4] - Total liabilities as of Q3 2021 amounted to ¥1,225,625,458.81, an increase from ¥1,162,211,826.93 in the previous year[28] - Current liabilities totaled ¥991,456,016.92, compared to ¥877,231,313.76 in Q3 2020, reflecting a growth of 13.0%[28] - Non-current liabilities decreased to ¥234,169,441.89 from ¥284,980,513.17 year-over-year, a decline of 17.8%[28] - The company's total equity was ¥2,592,000,000.00, with a capital reserve of ¥967,298,616.30, up from ¥963,095,015.97 in the previous year[28] Cash Flow - Cash flow from operating activities for the year-to-date was ¥216,285,018.38, a decrease of 12.37% compared to the same period last year[3] - The company reported a cash flow from operating activities of ¥319,799,858.54 for Q3 2021, compared to ¥286,304,422.09 in the same period last year[29] - The net cash flow from operating activities for the current period is ¥216,285,018.38, a decrease of 12.3% compared to ¥246,818,803.70 in the previous period[33] - The total cash inflow from investment activities is ¥669,876,764.38, down from ¥780,244,942.37 in the previous period, reflecting a decrease of 14.1%[33] - The net cash flow from financing activities is -¥92,423,177.27, an improvement from -¥184,643,873.65 in the previous period[34] Shareholder Information - The total number of common shareholders at the end of the reporting period is 25,631, with the top 10 shareholders holding a combined 56.73% of shares[12] - Li Shoujun, the largest shareholder, holds 41.42% of shares, totaling 167,474,479 shares, with 28,700,000 shares pledged[12] - The second-largest shareholder, Liang Wu, holds 5.87% of shares, totaling 23,716,898 shares[12] - The company has a total of 152,040,982 restricted shares at the end of the period, with no shares released during the reporting period[15] - The number of restricted shares held by Li Shoujun remains unchanged at 125,605,859 shares, locked until the end of the executive lock-up period[14] Business Segments - In the first three quarters of 2021, the company achieved operating revenue of CNY 1,498.95 million, a year-on-year increase of 2.58%[16] - The poultry business generated revenue of CNY 999.41 million, with a year-on-year increase of 1.44%[16] - The livestock business saw revenue of CNY 300.09 million, marking a significant year-on-year growth of 28.89%[16] - The pet business revenue reached CNY 19.45 million, reflecting a year-on-year increase of 15.16%[16] - The raw material drug business experienced a decline in revenue, totaling CNY 162.65 million, down 19.56% year-on-year[16] Research and Development - Research and development expenses increased to ¥85,769,408.06, up 17.6% from ¥72,899,951.48 in the same quarter last year[27] - The company is focusing on high-quality, comprehensive disease solutions to help clients reduce animal mortality rates and improve output[16] - The company has obtained new veterinary drug registration certificates and product approval numbers, enhancing its product line and market competitiveness[20] - The company is in the process of product transformation research and registration for the new antibiotic Tylosin derivative, which is expected to reduce bacterial resistance and expand the product line in the antibiotic sector[21] Market and Strategy - The company has not reported any new strategies or market expansions during this quarter[15] - There are no new products or technologies mentioned in the current report, focusing instead on existing shareholder structures and restrictions[15] - The demand for multi-category animal health products and one-stop services is increasing among large-scale livestock farmers due to complex farming environments and disease prevalence[16] - The company is accelerating external expansion and integration development to sustain rapid business growth[16] Miscellaneous - The company has not undergone an audit for the third quarter report[42] - The report indicates no adjustments made to prior comparative data under the new leasing standards[41] - The report was released by the board of directors on October 27, 2021[43]